Results 141 to 150 of about 1,228 (155)
Some of the next articles are maybe not open access.
Delafloxacin as a treatment option for community-acquired pneumonia infection
Expert Opinion on Pharmacotherapy, 2021Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality in adults. Bacterial pathogens are recognized to be frequent causative agents, which makes antibacterial treatment crucial for the evolution of these patients. There are several antimicrobial options available in daily practice.
openaire +2 more sources
What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2017Delafloxacin is a new fluoroquinolone antimicrobial approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults using dosage regimens of 300 mg intravenously every 12 hours, 450 mg orally every 12 hours, or switching from intravenous to oral regimens for a 5‐ to 14‐day treatment duration.
Cho, Jonathan C +3 more
openaire +3 more sources
Identification and Suppression of a Dimer Impurity in the Development of Delafloxacin
Organic Process Research & Development, 2008Delafloxacin is a 6-fluoroquinolone antibiotic which is under development at Rib-X Pharmaceuticals. During initial scale-up runs to prepare delafloxacin, up to 0.43% of a new impurity arose in the penultimate chlorination step. This was identified as a dimeric adduct of delafloxacin.
Roger Hanselmann +3 more
openaire +1 more source
Activity of delafloxacin versus that of levofloxacin against anaerobic and microaerophilic isolates
Anaerobe, 2020The aim of the study was to comparatively assess delafloxacin and levofloxacin activities against 96 anaerobic and some microaerophilic isolates. Delafloxacin minimal inhibitory concentrations (MICs) were strikingly lower than those of levofloxacin. Delafloxacin MIC90 against clostridia, other Gram-positive rods, anaerobic/microaerophilic cocci and ...
Lyudmila Boyanova +5 more
openaire +2 more sources
Pharmacokinetics of Intravenous Delafloxacin in Patients With End‐Stage Renal Disease
The Journal of Clinical Pharmacology, 2018AbstractThis was an open‐label, parallel‐group, crossover study that examined the pharmacokinetics and safety of delafloxacin, an anionic fluoroquinolone, after a single intravenous infusion in subjects with end‐stage renal disease (ESRD; creatinine clearance <15 mL/min) undergoing hemodialysis compared with healthy subjects.
Randall Hoover +5 more
openaire +2 more sources
Delafloxacin meglumine, Meropenem trihydrate/vaborbactam, Secnidazole, and Benznidazole
Journal of the American Pharmacists Association, 2018Daniel A, Hussar, Molly A, Walter
openaire +2 more sources